Related Experiment Videos
Single antiplatelet therapy for patients with previous gastrointestinal bleeds
Rochelle M Gellatly1, Margaret L Ackman
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Insights
For patients with a history of gastrointestinal bleeding (GIB) needing antiplatelet therapy, aspirin plus a proton pump inhibitor (PPI) is safer than clopidogrel. Aspirin plus PPI significantly reduces GIB recurrence compared to clopidogrel.
Area of Science:
- Cardiology
- Gastroenterology
- Pharmacology
Background:
- Patients with a history of gastrointestinal bleeding (GIB) require careful antiplatelet therapy selection for cardiovascular disease prevention.
- Aspirin and clopidogrel are commonly used antiplatelet agents.
- Proton pump inhibitors (PPIs) are often co-prescribed to mitigate GIB risk.
Purpose of the Study:
- To compare the efficacy and safety of aspirin plus a PPI versus clopidogrel in patients with a history of GIB.
- To determine the preferred antiplatelet strategy for secondary cardiovascular prevention in this high-risk population.
Main Methods:
- A systematic literature search was conducted across multiple databases (EMBASE, PubMed, Google) for relevant randomized trials.
- Included studies compared aspirin plus PPI with clopidogrel in patients with prior GIB requiring single antiplatelet therapy.
- Data on GIB recurrence rates were extracted and analyzed.
Main Results:
- Two randomized noninferiority trials were reviewed.
- Gastrointestinal bleed recurrences were significantly higher in the clopidogrel group (8.6% and 13.6%) compared to the aspirin plus PPI group (0.7% and 0%).
- The observed difference in GIB recurrence rates exceeded the pre-defined noninferiority margin.
Conclusions:
- Clopidogrel is not equivalent to aspirin plus a PPI in patients with a history of GIB requiring single antiplatelet therapy.
- Aspirin plus a PPI is clinically superior for reducing GIB recurrence in this patient population.
- Further research is needed for dual antiplatelet therapy in conjunction with PPIs.
Objective:
To determine whether aspirin plus a proton pump inhibitor (PPI) is preferable, from a gastrointestinal bleed (GIB) risk perspective, to clopidogrel in patients who have experienced a GIB while on aspirin and who require single antiplatelet therapy for secondary prevention of cardiovascular disease.
Data Sources:
A literature search was conducted using EMBASE (1980-January 2008), PubMed (1966-January 2008), Google, and a manual search of the reference lists using the search terms gastrointestinal bleed, gastrointestinal hemorrhage, peptic ulcer hemorrhage, ASA, aspirin, Plavix, clopidogrel, and PPI. The search, limited to human and English studies, yielded 110 returns.
Study Selection And Data Extraction:
Randomized trials that compared aspirin with clopidogrel, involved patients who had previously experienced a GIB, and provided detailed information on the type and dose of drugs used were included. Studies were required to provide information on the recurrence of GIB.
Data Synthesis:
Two randomized trials were reviewed to assess the safety of secondary prevention of cardiovascular disease with respect to previous GIB. These noninferiority trials compared aspirin plus a PPI with clopidogrel over 12 months following confirmed healing of an aspirin-induced ulcer. In both trials, the majority of the GIB recurrences were in the clopidogrel group (8.6% vs 0.7%; difference 7.9%; 95% CI 3.4 to 12.4; p = 0.001 and 13.6% vs 0%; difference 13.6%; 95% CI 6.3 to 20.9; p = 0.0019) and the difference in recurrence rates exceeded the a priori selected upper boundary.
Conclusions:
Findings reported in the limited literature available support that clopidogrel is not equivalent to the combination of aspirin plus a PPI in the patient population studied. Aspirin plus a PPI would be considered clinically superior and should be used in medically managed patients who require single antiplatelet therapy but have had a prior GIB while on aspirin. Further research regarding dual antiplatelet therapy and a PPI is required.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:27Peripheral Artery Disease III: Interprofessional Care
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...